US5523226A
(en)
|
1993-05-14 |
1996-06-04 |
Biotechnology Research And Development Corp. |
Transgenic swine compositions and methods
|
WO1999005266A2
(en)
|
1997-07-26 |
1999-02-04 |
Wisconsin Alumni Research Foundation |
Trans-species nuclear transfer
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
AU2884102A
(en)
|
2000-12-07 |
2002-06-18 |
Sangamo Biosciences Inc |
Regulation of angiogenesis with zinc finger proteins
|
AU2002225187A1
(en)
|
2001-01-22 |
2002-07-30 |
Sangamo Biosciences, Inc. |
Zinc finger polypeptides and their use
|
ES2409080T3
(es)
|
2001-01-22 |
2013-06-24 |
Sangamo Biosciences Inc. |
Proteínas de unión con dedos de zinc modificadas
|
AUPR446701A0
(en)
*
|
2001-04-18 |
2001-05-17 |
Gene Stream Pty Ltd |
Transgenic mammals for pharmacological and toxicological studies
|
AUPR451401A0
(en)
|
2001-04-20 |
2001-05-24 |
Monash University |
A method of nuclear transfer
|
WO2003087341A2
(en)
|
2002-01-23 |
2003-10-23 |
The University Of Utah Research Foundation |
Targeted chromosomal mutagenesis using zinc finger nucleases
|
WO2003078619A1
(en)
|
2002-03-15 |
2003-09-25 |
Cellectis |
Hybrid and single chain meganucleases and use thereof
|
US20030232410A1
(en)
|
2002-03-21 |
2003-12-18 |
Monika Liljedahl |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
US7612250B2
(en)
|
2002-07-29 |
2009-11-03 |
Trustees Of Tufts College |
Nuclear transfer embryo formation method
|
EP2806025B1
(en)
|
2002-09-05 |
2019-04-03 |
California Institute of Technology |
Use of zinc finger nucleases to stimulate gene targeting
|
AU2003290518A1
(en)
|
2002-09-06 |
2004-04-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions concerning designed highly-specific nucleic acid binding proteins
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
EP1591521A1
(en)
|
2004-04-30 |
2005-11-02 |
Cellectis |
I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
|
CA2579677A1
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
ES2667169T3
(es)
|
2004-10-19 |
2018-05-09 |
Regeneron Pharmaceuticals, Inc. |
Método para generar un animal no humano homocigótico para una modificación genética
|
WO2006097784A1
(en)
|
2005-03-15 |
2006-09-21 |
Cellectis |
I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
|
AU2006224248B2
(en)
|
2005-03-15 |
2011-01-06 |
Cellectis |
I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof
|
CN101117633B
(zh)
|
2006-08-03 |
2011-07-20 |
上海交通大学附属儿童医院 |
一种细胞核移植方法
|
MX2009006303A
(es)
|
2006-12-14 |
2009-10-21 |
Dow Agrosciences Llc |
Proteinas de dedo de zinc no canonicas optimizadas.
|
WO2009126161A1
(en)
|
2008-04-11 |
2009-10-15 |
Utc Fuel Cells, Llc |
Fuel cell and bipolar plate having manifold sump
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
EP2408921B1
(en)
|
2009-03-20 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
US20120178647A1
(en)
|
2009-08-03 |
2012-07-12 |
The General Hospital Corporation |
Engineering of zinc finger arrays by context-dependent assembly
|
WO2011020005A1
(en)
|
2009-08-14 |
2011-02-17 |
Regeneron Pharmaceuticals, Inc. |
miRNA-REGULATED DIFFERENTIATION-DEPENDENT SELF-DELETING CASSETTE
|
ES2908587T3
(es)
|
2009-10-06 |
2022-05-03 |
Regeneron Pharma |
Ratones modificados genéticamente e injerto
|
WO2011059799A1
(en)
|
2009-10-29 |
2011-05-19 |
Regeneron Pharmaceuticals, Inc. |
Multifunctional alleles
|
AU2010327998B2
(en)
|
2009-12-10 |
2015-11-12 |
Iowa State University Research Foundation, Inc. |
TAL effector-mediated DNA modification
|
DK3375284T3
(da)
|
2011-02-15 |
2023-06-12 |
Univ Yale |
Humaniserede M-CSF-mus og anvendelser deraf
|
NO2718319T3
(ko)
|
2011-06-07 |
2018-05-05 |
|
|
AU2012312260B2
(en)
|
2011-09-21 |
2017-08-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
SI2770821T1
(en)
|
2011-10-28 |
2018-01-31 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex of mice
|
SG10201600965YA
(en)
|
2011-10-28 |
2016-03-30 |
Regeneron Pharma |
Humanized il-6 and il-6 receptor
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
WO2013141680A1
(en)
|
2012-03-20 |
2013-09-26 |
Vilnius University |
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
|
DK2839013T3
(da)
|
2012-04-18 |
2020-09-14 |
Univ Leland Stanford Junior |
Ikke-disruptiv-gen-targetering
|
PL2847335T3
(pl)
|
2012-04-25 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Celowanie dużymi wektorami do celowania wspomagane nukleazą
|
DE202013012242U1
(de)
|
2012-05-25 |
2016-02-02 |
Emmanuelle Charpentier |
Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
|
US8962913B2
(en)
|
2012-06-18 |
2015-02-24 |
Regeneron Pharmaceuticals, Inc. |
Humanized IL-7 rodents
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
WO2014011237A1
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for the treatment of lysosomal storage diseases
|
WO2014033644A2
(en)
|
2012-08-28 |
2014-03-06 |
Novartis Ag |
Methods of nuclease-based genetic engineering
|
DE202013012597U1
(de)
|
2012-10-23 |
2017-11-21 |
Toolgen, Inc. |
Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung
|
EP3556206B1
(en)
|
2012-11-05 |
2021-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals and methods of use thereof
|
JP2016500254A
(ja)
|
2012-12-05 |
2016-01-12 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
代謝疾患の調節のための方法および組成物
|
PL3138910T3
(pl)
|
2012-12-06 |
2018-01-31 |
Sigma Aldrich Co Llc |
Oparta na CRISPR modyfikacja i regulacja genomu
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
WO2014099744A1
(en)
|
2012-12-17 |
2014-06-26 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
EP2958990B1
(en)
|
2013-02-20 |
2019-10-16 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
JP6444321B2
(ja)
|
2013-02-22 |
2018-12-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ヒト化主要組織適合性遺伝子複合体を発現するマウス
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
JP2016507244A
(ja)
|
2013-02-27 |
2016-03-10 |
ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト(ゲーエムベーハー)Helmholtz Zentrum MuenchenDeutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH) |
Cas9ヌクレアーゼによる卵母細胞における遺伝子編集
|
KR102210319B1
(ko)
|
2013-03-15 |
2021-02-01 |
더 제너럴 하스피탈 코포레이션 |
특정 게놈 좌위에 대한 유전적 및 후성적 조절 단백질의 rna-안내 표적화
|
WO2014165825A2
(en)
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
HUE040575T2
(hu)
|
2013-04-16 |
2019-03-28 |
Regeneron Pharma |
A patkány genom célzott módosítása
|
US10604771B2
(en)
|
2013-05-10 |
2020-03-31 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
BR112015031608A2
(pt)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
|
RS64573B1
(sr)
|
2013-09-23 |
2023-10-31 |
Regeneron Pharma |
Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom
|
US20160237455A1
(en)
|
2013-09-27 |
2016-08-18 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
SI3138397T1
(sl)
|
2013-10-15 |
2019-04-30 |
Regeneron Pharmaceuticals, Inc. |
Humanizirane živali IL-15
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
ES2813367T3
(es)
|
2013-12-09 |
2021-03-23 |
Sangamo Therapeutics Inc |
Métodos y composiciones para ingeniería genómica
|
MX2016007654A
(es)
|
2013-12-11 |
2017-08-15 |
Regeneron Pharma |
Metodos y composiciones para la modificacion dirigida de un genoma.
|
EP3079726B1
(en)
|
2013-12-12 |
2018-12-05 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
KR20220100728A
(ko)
|
2014-03-21 |
2022-07-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴클레아제 없는 게놈 편집
|
RU2020103811A
(ru)
|
2014-05-05 |
2020-02-18 |
Регенерон Фармасьютикалз, Инк. |
Гуманизированные животные по с5 и с3
|
NO2785538T3
(ko)
|
2014-05-07 |
2018-08-04 |
|
|
DK3841877T3
(da)
|
2014-05-19 |
2023-11-27 |
Regeneron Pharma |
Genetisk modificeret mus, der eksprimerer human EPO
|
CA2951707A1
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
CN106852157B
(zh)
|
2014-06-16 |
2022-04-12 |
约翰斯·霍普金斯大学 |
用于使用h1启动子表达crispr向导rna的组合物和方法
|
HUE049405T2
(hu)
|
2014-06-23 |
2020-09-28 |
Regeneron Pharma |
Nukleáz-közvetített DNS-összeállítás
|
US20150376586A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
HUE041584T2
(hu)
|
2014-06-26 |
2019-05-28 |
Regeneron Pharma |
Célzott genetikai módosítások és alkalmazási módszerek és készítmények
|
US10342761B2
(en)
|
2014-07-16 |
2019-07-09 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
WO2016044745A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
LT3221457T
(lt)
|
2014-11-21 |
2019-06-10 |
Regeneron Pharmaceuticals, Inc. |
Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
HRP20231039T1
(hr)
|
2015-04-06 |
2023-12-22 |
Regeneron Pharmaceuticals, Inc. |
Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja
|
WO2016197133A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics, Inc. |
Delivering crispr therapeutics with lipid nanoparticles
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
EP3322297A4
(en)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
RELEASE METHOD AND COMPOSITIONS FOR NUCLEASE-DERIVED GENOMINE ENGINEERING
|
EP3159407A1
(en)
|
2015-10-23 |
2017-04-26 |
Silence Therapeutics (London) Ltd |
Guide rnas, methods and uses
|
BR112018008519A2
(pt)
|
2015-10-28 |
2018-11-06 |
Sangamo Therapeutics Inc |
construtos específicos de fígado, cassetes de expressão de fator viii e métodos de uso dos mesmos
|
MX2018005332A
(es)
|
2015-11-06 |
2018-11-09 |
Crispr Therapeutics Ag |
Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
|
KR102454546B1
(ko)
|
2015-11-20 |
2022-10-14 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
|
AU2016361350B2
(en)
|
2015-11-23 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
JP6932698B2
(ja)
|
2015-12-01 |
2021-09-08 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG |
アルファ1アンチトリプシン欠乏症の治療のための材料および方法
|
BR112018012894A2
(pt)
|
2015-12-23 |
2018-12-04 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
|
EP3411078A1
(en)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
KR102487839B1
(ko)
|
2016-02-04 |
2023-01-12 |
리제너론 파마슈티칼스 인코포레이티드 |
조작된 angptl8 유전자를 갖는 비인간 동물
|
EP3416689B1
(en)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
US20190136231A1
(en)
|
2016-03-30 |
2019-05-09 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle formulations for crispr/cas components
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11674158B2
(en)
|
2016-07-15 |
2023-06-13 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
MX2019004487A
(es)
|
2016-10-20 |
2020-02-07 |
Sangamo Therapeutics Inc |
Metodos y composiciones para el tratamiento de la enfermedad de fabry.
|
BR112019011509A2
(pt)
|
2016-12-08 |
2020-01-28 |
Intellia Therapeutics Inc |
rnas guias modificados
|
US20180185516A1
(en)
|
2016-12-09 |
2018-07-05 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
EP3562515A4
(en)
|
2016-12-29 |
2020-11-18 |
Applied StemCell, Inc. |
GENE EDITING PROCESS USING A VIRUS
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
MX2019010219A
(es)
|
2017-02-27 |
2020-02-07 |
Regeneron Pharma |
Modelo humanizado de trastornos renales y hepáticos.
|
EP3640335A4
(en)
|
2017-06-15 |
2021-03-31 |
Toolgen Incorporated |
PLATFORM FOR EXPRESSION OF A PROTEIN OF INTEREST IN THE LIVER
|
US11981898B2
(en)
|
2017-06-16 |
2024-05-14 |
Applied Stemcell, Inc. |
Gene editing methods with increased knock-in efficiency
|
EP4276185A3
(en)
|
2017-09-29 |
2024-02-21 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
KR20200067190A
(ko)
|
2017-10-17 |
2020-06-11 |
크리스퍼 테라퓨틱스 아게 |
A형 혈우병을 위한 유전자 편집용 조성물 및 방법
|
CN111727251A
(zh)
|
2017-11-21 |
2020-09-29 |
克里斯珀医疗股份公司 |
用于治疗常染色体显性色素性视网膜炎的材料和方法
|
CA3084185A1
(en)
|
2017-12-06 |
2019-06-13 |
Generation Bio Co. |
Gene editing using a modified closed-ended dna (cedna)
|
US20230201373A1
(en)
|
2017-12-15 |
2023-06-29 |
Regents Of The University Of Minnesota |
Crispr-mediated genome editing with vectors
|
CN111886341A
(zh)
|
2018-01-05 |
2020-11-03 |
香港中文大学 |
使用crispr的高效体内敲入
|
EP3737762A1
(en)
|
2018-01-12 |
2020-11-18 |
CRISPR Therapeutics AG |
Compositions and methods for gene editing by targeting transferrin
|
WO2019161310A1
(en)
|
2018-02-16 |
2019-08-22 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
CA3093850A1
(en)
|
2018-03-26 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
CA3102950A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Modified guide rnas for gene editing
|
JP2021528426A
(ja)
|
2018-06-19 |
2021-10-21 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物
|
WO2020006131A2
(en)
|
2018-06-27 |
2020-01-02 |
Altius Institute For Biomedical Sciences |
Nucleases for genome editing
|
EP3814493A4
(en)
|
2018-06-27 |
2022-03-30 |
Altius Institute For Biomedical Sciences |
NUCLEIC ACID BINDING DOMAINS AND METHODS OF USE THEREOF
|
EP3814524A4
(en)
|
2018-06-27 |
2022-04-27 |
Altius Institute For Biomedical Sciences |
GAP AND TUNABLE REPEAT UNIT FOR USE IN GENOME EDITING AND GENE REGULATION COMPOSITIONS
|
CN116200426A
(zh)
|
2018-07-16 |
2023-06-02 |
瑞泽恩制药公司 |
Ditra疾病的非人动物模型及其用途
|
CN113166748A
(zh)
|
2018-08-10 |
2021-07-23 |
逻辑生物治疗公司 |
用于治疗mma的非破坏性基因疗法
|
WO2020079033A1
(en)
|
2018-10-15 |
2020-04-23 |
Fondazione Telethon |
Genome editing methods and constructs
|
MX2021004455A
(es)
|
2018-10-17 |
2021-08-11 |
Crispr Therapeutics Ag |
Composiciones y métodos para administrar transgenes.
|
WO2020082047A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
MX2021004282A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Construcciones de ácido nucleico y métodos de uso.
|
JP7472121B2
(ja)
|
2018-10-18 |
2024-04-22 |
インテリア セラピューティクス,インコーポレーテッド |
アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法
|
CA3116331A1
(en)
*
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor ix
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
AU2020221340A1
(en)
|
2019-02-15 |
2021-09-16 |
Bayer Healthcare Llc |
Gene editing for hemophilia A with improved Factor VIII expression
|
AU2020256225A1
(en)
|
2019-04-03 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
IL286905B1
(en)
|
2019-04-04 |
2024-02-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
WO2020210552A1
(en)
|
2019-04-11 |
2020-10-15 |
California Institute Of Technology |
Methods and compositions for in vivo gene editing based cell-type-specific cellular engineering
|
KR20220015385A
(ko)
|
2019-05-30 |
2022-02-08 |
국립대학법인 홋가이도 다이가쿠 |
지질 나노 입자
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
KR20220017939A
(ko)
|
2019-06-07 |
2022-02-14 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 알부민 좌위를 포함하는 비-인간 동물
|
WO2021072115A1
(en)
|
2019-10-08 |
2021-04-15 |
Regents Of The University Of Minnesota |
Crispr-mediated human genome editing with vectors
|
WO2021083073A1
(zh)
|
2019-10-31 |
2021-05-06 |
华东师范大学 |
一种基于肝细胞Alb基因的疾病治疗的产品
|
AU2021269103A1
(en)
|
2020-05-06 |
2022-12-15 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|